ライフサイエンスコーパス: antitumour

1 have similar structures, but differ in their antitumour activities and ecophysiological roles.

2 tecture of the tumour and by suppressing the antitumour activities of immune cells, thus generating a

3 using NCPs as nanotherapeutics with enhanced antitumour activities, this study establishes NCPs as a

4 d fumaric acids) that showed antioxidant and antitumour activities, without hepatotoxicity.

5 enetration and resulted in markedly enhanced antitumour activity (compared with administration of fre

6 The decoction exhibited no antitumour activity (GI(50)>400 mug/mL) which could indi

7 safety profile with encouraging preliminary antitumour activity across multiple tumour types in heav

8 mittent schedules of a RAF-MEK inhibitor has antitumour activity across various cancers with RAF-RAS-

9 6), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; howeve

10 Both dual mTOR/PI3K inhibitors demonstrated antitumour activity against all xenografts tested.

11 Olaparib has antitumour activity against metastatic castration-resist

12 peutic DNA vaccine plus pembrolizumab showed antitumour activity against recurrent or advanced cervic

13 Antitumour activity analyses are based on all patients w

14 nts a new therapy with clinically meaningful antitumour activity and a manageable safety profile in p

15 represent a new targeted therapy with robust antitumour activity and a manageable safety profile in p

16 INTERPRETATION: First-line pembrolizumab has antitumour activity and acceptable tolerability in cispl

17 metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in

18 Cemiplimab showed antitumour activity and an acceptable safety profile in

19 The combination has promising antitumour activity and further clinical development is

20 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line

21 Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients wi

22 Pembrolizumab showed antitumour activity and manageable toxicity in early-pha

23 a pan-PI3K inhibitor, has shown preclinical antitumour activity and objective responses in patients

24 ntibodies linked to streptavidin to evaluate antitumour activity and pre-clinical safety.

25 interleukin 1alpha, has been associated with antitumour activity and relief of debilitating symptoms

26 nal anti-PD-L1 antibody, has shown promising antitumour activity and safety in this disease.

27 world study provides evidence supporting the antitumour activity and safety of cabozantinib across no

28 We aimed to assess the antitumour activity and safety of dabrafenib plus tramet

29 We investigated the antitumour activity and safety of lorlatinib in advanced

30 ndrogen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with th

31 We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmun

32 We aimed to assess the antitumour activity and safety of tafasitamab plus lenal

33 We aimed to assess antitumour activity and safety of targeted therapy or co

34 of olaparib and durvalumab showed promising antitumour activity and safety similar to that previousl

35 We sought to analyse the antitumour activity and toxicity of cabozantinib in adva

36 ed analysis assessed the association between antitumour activity and tTMB in treated patients with ev

37 Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent gliob

38 Regorafenib has antitumour activity as first-line treatment for metastat

39 D-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in

40 he basket dose-expansion phase, we evaluated antitumour activity at the recommended phase 2 dose, det

41 Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth

42 ression endpoints was July 30, 2018, and for antitumour activity endpoints was May 17, 2019.

43 liferation, phenotype, effector function and antitumour activity in a mouse model of B-cell lymphoma.

44 targeted nano-assembly exhibits significant antitumour activity in a mouse tumour model.

45 ble derivative of calcein, shows significant antitumour activity in a wide spectrum of cultured cance

46 e 2 dose of pembrolizumab and its safety and antitumour activity in advanced paediatric cancer.

47 suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring

48 determine its safety, pharmacokinetics, and antitumour activity in children and young adults with re

49 is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers.

50 nisms of inhibition are required for optimal antitumour activity in each genotype.

51 receptor alpha monoclonal antibody that has antitumour activity in human sarcoma xenografts.

52 Despite their outstanding antitumour activity in mice, the limited supply from the

53 mentary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing bre

54 The conjugate showed a potent antitumour activity in mouse models that led to the erad

55 ty through multiple mechanisms and augmented antitumour activity in multiple malignancies.

56 ab was well tolerated and showed encouraging antitumour activity in paediatric patients with relapsed

57 anageable safety profile and has preliminary antitumour activity in patients with advanced PDGFRA D84

58 ase inhibitor (TKI) crizotinib showed marked antitumour activity in patients with advanced, ALK-posit

59 Alectinib was well tolerated, with promising antitumour activity in patients with ALK-rearranged NSCL

60 BRAF inhibition has shown antitumour activity in patients with BRAF(V600E)-mutant

61 rapamycin (mTOR) inhibitor with single-agent antitumour activity in patients with mantle cell lymphom

62 eptable risk-benefit profile and encouraging antitumour activity in patients with MET-amplified, EGFR

63 Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneou

64 ose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive,

65 bined with trametinib, has shown substantial antitumour activity in patients with previously treated

66 a manageable safety profile with favourable antitumour activity in patients with previously treated

67 umab showed an acceptable safety profile and antitumour activity in patients with progressive or trea

68 Vemurafenib showed antitumour activity in patients with progressive, BRAF(V

69 ession or ETS rearrangements and measures of antitumour activity in patients with prostate cancer.

70 itors combined with immunotherapy have shown antitumour activity in preclinical studies.

71 rated and demonstrated clinically meaningful antitumour activity in recurrent or metastatic squamous

72 factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer.

73 VEG-ECT demonstrated encouraging antitumour activity in soft-tissue malignancies; a singl

74 Pembrolizumab had low antitumour activity in the majority of paediatric tumour

75 olizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1-2 ECHO-202/KEYNOTE-03

76 INTERPRETATION: Avelumab showed antitumour activity in the treatment of patients with pl

77 This combination therapy showed preliminary antitumour activity in this interim analysis, which coul

78 Preclinical studies showed promising antitumour activity in various models.

79 ll immune responses and exhibits significant antitumour activity in vivo.

80 Both oral agents have antitumour activity in women with recurrent ovarian canc

81 owed a manageable tolerability profile, with antitumour activity irrespective of PD-L1 status, and wa

82 se molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigatio

83 Antitumour activity observed for 43 natural and 10 comme

84 Despite compelling antitumour activity of antibodies targeting the programm

85 imed to assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT and PDGF

86 present a primary analysis of the safety and antitumour activity of cemiplimab in patients with local

87 n the trial, we believe that the preliminary antitumour activity of cereblon modulators plus next-gen

88 ase inhibitor, has been shown to enhance the antitumour activity of chemotherapy and radiotherapy in

89 addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with met

90 inistration of an ERK inhibitor enhances the antitumour activity of CHK2 inhibition in both a human D

91 ne the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refra

92 ding Ewing's sarcoma, and early reports show antitumour activity of IGF-1R-targeting drugs in these d

93 ed to evaluate the safety, tolerability, and antitumour activity of margetuximab plus pembrolizumab (

94 We aimed to assess the safety and antitumour activity of navitoclax in patients with lymph

95 nd pharmacodynamic profiles, and preliminary antitumour activity of niraparib.

96 ic exposure, maximum tolerated dose, and the antitumour activity of nivolumab at the adult recommende

97 imed to assess the safety, tolerability, and antitumour activity of pembrolizumab, a humanised anti-p

98 assess the safety, side-effect profile, and antitumour activity of pembrolizumab.

99 This study evaluated the safety and antitumour activity of pemigatinib in patients with prev

100 e aimed to assess the safety and preliminary antitumour activity of ramucirumab (an IgG1 VEGFR-2 anta

101 We assessed the antitumour activity of sonidegib, a Hedgehog signalling

102 However, as experience grows with the antitumour activity of these drugs, new toxic effects ar

103 recommended phase 2 dose, and the safety and antitumour activity of this dose were assessed.

104 ttent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid

105 n-naive) treated with avelumab and to assess antitumour activity of this drug in post-platinum patien

106 , tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed popu

107 antibody tremelimumab might provide greater antitumour activity than either drug alone.

108 have a higher therapeutic index and greater antitumour activity than mitogen-activated protein kinas

109 c epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action.

110 Preliminary antitumour activity warrants further evaluation.

111 Antitumour activity was also recorded in brain metastase

112 Antitumour activity was also reported in sporadic high-g

113 Antitumour activity was assessed in post-platinum patien

114 In vivo antitumour activity was assessed in Sarcoma 180-bearing

115 eded 50% at doses greater than 80 mg/day and antitumour activity was documented beyond doses of 60 mg

116 -mutant non-melanoma solid tumours, apparent antitumour activity was noted in a gastrointestinal stro

117 Safety and antitumour activity were evaluated at data cutoff on Jun

118 egion showed 87.50+/-5.50% and 79.00+/-5.56% antitumour activity which were reference standard.

119 e, trilaciclib has the potential to optimise antitumour activity while minimising myelotoxicity.

120 umab tesirine shows encouraging single-agent antitumour activity with a manageable safety profile.

121 umab tesirine shows encouraging single-agent antitumour activity with a manageable safety profile.

122 therapy and nivolumab plus ipilimumab showed antitumour activity with durable responses and manageabl

123 Previous phase 2 studies have shown antitumour activity with gemcitabine and oxaliplatin (GE

124 We recorded encouraging antitumour activity with MDV3100 in patients with castra

125 ngs serve as proof of concept of synergistic antitumour activity with the combination of an Fc-optimi

126 GEMOX-B showed antitumour activity with tolerable safety in patients wi

127 In a preliminary assessment of antitumour activity, 21 (55% [95% CI 38-71]) of 38 patie

128 ts that dasatinib kinase inhibition leads to antitumour activity, affects osteoclasts, and has synerg

129 enhances antigen-specific T-cell migration, antitumour activity, and has favourable toxicity.

130 e modulation of TH9 cell differentiation and antitumour activity, and prompt potential autophagy-depe

131 numerous physiological properties including antitumour activity, especially in colon cancer.

132 dy population, trastuzumab deruxtecan showed antitumour activity, even in low HER2-expressing tumours

133 taxel plus prednisone has important clinical antitumour activity, improving overall survival in patie

134 Despite this robust antitumour activity, most responses to these drugs are p

135 a manageable toxicity profile and promising antitumour activity, warranting further study in phase 2

136 manageable toxicity profile and preliminary antitumour activity.

137 bution lymphocytosis, leading to more potent antitumour activity.

138 CD4(+) immunogenic mutations confers strong antitumour activity.

139 dpoints included pharmacodynamic effects and antitumour activity.

140 ompounds with high antioxidant potential and antitumour activity.

141 ted here, and is associated with substantial antitumour activity.

142 ynamic effects on platelets and T cells, and antitumour activity.

143 The therapeutic landscape of antitumour agents targeting the DDR has rapidly expanded

144 f OVs with different immune modifiers and/or antitumour agents, based on mechanisms of tumour resista

145 ituent responsible for the antiinflammatory, antitumour and antioxidant activities of ginger.

146 The potential antitumour and disease-modifying role of adjuvant bispho

147 erial, antifungal, antiviral, antiparasitic, antitumour, anti-inflammatory, antioxidant, and immunomo

148 We utilized the antitumour antibiotic CoII(Chro)2 (Chro = chromomycin A3

149 cin A is a member of a subfamily of enediyne antitumour antibiotics characterized by a 10-membered ca

150 en pretargeted with a relevant FITC-labelled antitumour antibody.

151 several areas of bio-applications, including antitumour, antimicrobial, antioxidant and bioengineerin

152 Oxetanocin A (OXT-A) is a potent antitumour, antiviral and antibacterial compound.

153 one of a number of cytokines that can induce antitumour CD8(+) T cell responses.

154 ization of immune cells capable of producing antitumour cytokines and effectively killing tumour cell

155 ted encapsulation can reduce the toxicity of antitumour drugs and improve their efficacy.

156 s of this plant are the main source of these antitumour drugs, much remains unknown on how TIAs are b

157 cyte (CTL) response, can result in promising antitumour effect against several human malignancies, es

158 In the clinical setting the antitumour effect is less clear, but recent data suggest

159 riggered cancer cell death and amplified the antitumour effect of 4T-Trap.

160 The impaired antitumour effect of CD4(+) T cells with their defective

161 tor and that inhibition of TIM3 enhances the antitumour effect of PD1 blockade.

162 o treat melanoma in mice and observed a good antitumour effect.

163 of T lymphocytes, resulting in highly potent antitumour effect.

164 iderable clinical benefit, such as increased antitumour effects and improved survival.

165 Significant antitumour effects are observed in piperlongumine-treate

166 We noted antitumour effects at all doses, including decreases in

167 Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoi

168 relevance, particularly with respect to the antitumour effects of aspirin.

169 Preclinical studies have reported direct antitumour effects of bisphosphonates, particularly in c

170 is study aimed to investigate the safety and antitumour effects of pamiparib, an oral PARP 1/2 inhibi

171 This study investigated the antitumour effects of two dual mTOR/PI3K inhibitors, ged

172 ompetitive RAF kinase inhibitors have potent antitumour effects on mutant BRAF(V600E) tumours but, in

173 ABP4 by siRNA in vivo has antiangiogenic and antitumour effects with minimal toxicity and should be i

174 ions at SMO have been found to abolish their antitumour effects, a phenomenon known as chemoresistanc

175 ostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid development over the

176 etic and toxicological profiles and dramatic antitumour efficacy in vivo.

177 suggest that platelets may be central to the antitumour efficacy of aspirin.

178 ion after cisplatin without compromising the antitumour efficacy of cisplatin.

179 We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advan

180 of immunogenic nanoparticles to augment the antitumour efficacy of PD-L1 antibody-mediated cancer im

181 Further studies are needed to confirm the antitumour efficacy of the combination of a somatostatin

182 ticles act similarly to Metformin and induce antitumour efficacy through activation of the AMPK and i

183 mpatibility; as a result, we achieved better antitumour efficacy.

184 -related cardiotoxicity without compromising antitumour efficacy.

185 Ferroptosis contributes to the antitumour function of several tumour suppressors such a

186 l as the effects of epigenetic modulation on antitumour immune cell function.

187 ovide evidence to support the presence of an antitumour immune response in advanced thyroid cancers l

188 ailures in mounting a sufficient and lasting antitumour immune response(3,4).

189 t different RT responses primarily due to an antitumour immune response.

190 microenvironment as an important part of the antitumour immune response.

191 2-targeted phagocytosis and produced durable antitumour immune responses against HER2-expressing tumo

192 ve important roles in generating spontaneous antitumour immune responses and predicting clinical resp

193 Endogenous or iatrogenic antitumour immune responses can improve the course of fo

194 mmunotherapy has been shown to induce potent antitumour immune responses in many cancers including HN

195 her they are sufficient to induce protective antitumour immune responses or whether their expression

196 nce, immunity and immunosuppression regulate antitumour immune responses together with the advent of

197 hibitors of epigenetic regulators to enhance antitumour immune responses, and discuss the challenges

198 th DC stimuli induced potent T-cell-mediated antitumour immune responses, resulting in tumour eradica

199 wn that PDL1-expressing exosomes can inhibit antitumour immune responses.

200 ocytosis checkpoint blockade on induction of antitumour immune responses.

201 egies that modulate both innate and adaptive antitumour immune responses.

202 cal studies have found radiotherapy enhances antitumour immune responses.

203 ulatory checkpoints and unleash pre-existing antitumour immune responses.

204 r critical involvement in shaping the body's antitumour immune responses.

205 ctivity of tumour cells, leading to impaired antitumour immune responses.

206 bodies and associated effector cells in both antitumour immune surveillance and therapy.

207 n have the desired outcome of reinvigorating antitumour immune surveillance, but often at the expense

208 and simultaneously generates potent systemic antitumour immunity against poorly immunogenic B16F10 in

209 mBiNE was receptor dependent, the subsequent antitumour immunity also generated protective effects ag

210 the ROS in tumour microenvironment elicited antitumour immunity and increased infiltration of T lymp

211 d DCs as a powerful inducer of Th9 cells and antitumour immunity and may have important clinical impl

212 ributes to the induction of antigen-specific antitumour immunity and pathogenesis of graft-versus-hos

213 iscuss how these metabolic circuits regulate antitumour immunity and the possible approaches to targe

214 d to investigate the prognostic role of host antitumour immunity as represented by baseline quantitie

215 rall survival, suggesting that the effect of antitumour immunity extends to the advanced setting.

216 rall survival, suggesting that the effect of antitumour immunity extends to the advanced setting.

217 targeting the metabolic circuits that impede antitumour immunity have been developed, with several cl

218 New therapies that promote antitumour immunity have been recently developed.

219 ing cytotoxic therapy to successfully engage antitumour immunity in breast cancer.

220 ibited clear treatment efficacy and systemic antitumour immunity in ovarian, colon, and breast tumour

221 mitate, or the silencing of DHHC3, activates antitumour immunity in vitro and in mice bearing MC38 tu

222 r-binding allogeneic IgG can induce powerful antitumour immunity that can be exploited for cancer imm

223 nges may be an effective strategy to enhance antitumour immunity that prevents tumour progression, as

224 ow they could be combined with biomarkers of antitumour immunity to optimize radiotherapy regimens an

225 elp establish local conditions that suppress antitumour immunity to promote tumorigenesis.

226 ression and subsequently stimulates systemic antitumour immunity to treat metastases.

227 essive neutrophils during cisplatin therapy, antitumour immunity was activated in this poorly immunog

228 mmune systems elicit strong and long lasting antitumour immunity which prevents tumour formation when

229 omeostasis, but are a significant barrier to antitumour immunity(1).

230 CD8(+) T cells have a central role in antitumour immunity, but their activity is suppressed in

231 iscovery of biological processes critical to antitumour immunity, namely interferon signalling and an

232 d the mechanisms by which tumour cells evade antitumour immunity, the field of cancer immunotherapy h

233 Mechanistically, LCMV induces antitumour immunity, which depends on the recruitment of

234 ion in the tumour microenvironment restricts antitumour immunity.

235 1 to negatively modulate TH9 homeostasis and antitumour immunity.

236 ro-inflammatory extracellular ATP to restore antitumour immunity.

237 egulating immune cell function and mediating antitumour immunity.

238 ells (APCs) is critical to the generation of antitumour immunity.

239 vascular sites has emerged as a key step in antitumour immunity.

240 sponse, supported by analogies in cancer and antitumour immunity.

241 cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity.

242 -associated inflammation actively suppresses antitumour immunity.

243 at promotes immune resistance and attenuates antitumour immunity.

244 ous immune functions in support of effective antitumour immunity.

245 ent (TME) and thus limited reinvigoration of antitumour immunity.

246 g to the surveillance of cellular damage and antitumour immunity.

247 c and extrinsic factors that may impact host antitumour immunity.

248 s, and enhances STING-mediated antiviral and antitumour immunity.

249 stimulate tumour microenvironments to elicit antitumour immunity.

250 istetraprolin, contributing to regulation of antitumour immunity.IL-27 is one of a number of cytokine

251 rance of the glioblastoma and a long-lasting antitumour memory response.

252 owth, suggesting the generation of long-term antitumour memory.

253 Treatment advances include antitumour necrosis factor- alpha drugs; however, these

254 and case reports using mainly rituximab and antitumour necrosis factor-alpha agents to treat these d

255 fficacy, the main exception being the use of antitumour necrosis factor-alpha agents with cyclophosph

256 e-modifying antirheumatic drugs (DMARDs) and antitumour necrosis factor-alpha biologic agents.

257 MTX and antitumour necrosis factor-alpha drugs also appear to ha

258 enotypic cell state transition for improving antitumour outcome could emerge as a translational strat

259 power and lipid peroxidation inhibition) and antitumour potential (against breast, lung, cervical and

260 dy focuses on exploration of antioxidant and antitumour potential as well as total phenolic contents

261 Antitumour potential of honey is attributed to its excel

262 i honeys possessed excellent antioxidant and antitumour potential overall.

263 ochemicals with bioactive properties (mainly antitumour potential selective to colon and cervical car

264 er and inhibition of lipid peroxidation; the antitumour potential was tested in human tumour cell lin

265 er and inhibition of lipid peroxidation, the antitumour potential was tested in human tumour cell lin

266 a lower antioxidant potential and absence of antitumour potential.

267 targeting cancer-associated fibroblasts had antitumour properties.

268 n that can be targeted in the development of antitumour reagents.

269 ticipating in cellular networks that mediate antitumour resistance.

270 anocarrier leads to a significantly improved antitumour response in both breast cancer and melanoma m

271 Here we report a new mechanism by which the antitumour response of mouse CD8(+) T cells can be poten

272 e with dectin-1-activated DCs induces potent antitumour response that depends on Th9 cells and IL-9 i

273 This antitumour response, however, is likely blunted by the p

274 objectives were safety and tolerability, and antitumour response.

275 s and is thereby a negative regulator of the antitumour response.

276 nd adaptive immunity and promote a universal antitumour response.

277 w an elevated antigen-specific CD8(+) T cell antitumour response.

278 generally well tolerated and associated with antitumour responses and clinical benefit in patients wi

279 Conversely, neutrophils can also mediate antitumour responses by direct killing of tumour cells a

280 Although the role of T cells in antitumour responses has thoroughly been studied, other

281 on of cytotoxic T cells, leading to improved antitumour responses in vivo, and elicited proportionall

282 immunogenicity and immune cells involved in antitumour responses may also be affected by epigenomic

283 anomas to investigate the role of B cells in antitumour responses, and find that the co-occurrence of

284 t of REGNASE-1 and as a rheostat that shapes antitumour responses.

285 itical for priming effective and therapeutic antitumour responses.

286 The heterogeneity among the antioxidant and antitumour results of the samples and some low correlati

287 pathways exploited by tumours is a promising antitumour strategy, especially when combined with other

288 In the in vivo antitumour study, tumour growth inhibition rates were 31

289 PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity.

290 ng by gefitinib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of P

291 wever, whether dectin-1 directs DCs to prime antitumour Th9 cells remains unclear.

292 mour-specific antigens (TSAs) as targets for antitumour therapies has accelerated within the past dec

293 hich may act as a critical block to existing antitumour therapies.

294 mmunostimulatory, increasing the efficacy of antitumour therapies.

295 afts, enabling an effective single-treatment antitumour therapy.

296 basic cancer biology and the development of antitumour therapy.

297 s, E7130 significantly augment the effect of antitumour treatments in mouse models and is currently i

298 hat HM-3A is worth further investigation for antitumour use.

299 n calreticulin exposure on the cell surface, antitumour vaccination and an abscopal effect.

300 The formulations of peptide-based antitumour vaccines being tested in clinical studies are